세계의 망막정맥폐쇄증 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Retinal Vein Occlusion Market - Scope of Report

TMR's report on the global retinal vein occlusion market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global retinal vein occlusion market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global retinal vein occlusion market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the retinal vein occlusion market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global retinal vein occlusion market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global retinal vein occlusion market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global retinal vein occlusion market.

The report delves into the competitive landscape of the global retinal vein occlusion market. Key players operating in the global retinal vein occlusion market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global retinal vein occlusion market profiled in this report.

Key Questions Answered in Global retinal vein occlusion Market Report:

• What is the sales/revenue generated by retinal vein occlusion across all regions during the forecast period?
• What are the opportunities in the global retinal vein occlusion market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Retinal Vein Occlusion Market - Research Objectives and Research Approach

The comprehensive report on the global retinal vein occlusion market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global retinal vein occlusion market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global retinal vein occlusion market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Retinal Vein Occlusion Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Retinal Vein Occlusion Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory Scenario
• 5.2. PESTLE Analysis
• 5.3. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
• 5.4. Go-to-Market Strategies for Retinal Vein Occlusion Market
• 5.5. Value Chain Analysis
• 5.6. Treatment Algorithm
• 5.7. Key Industry Events

6. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Disease Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Disease Type, 2020-2034
  • 6.3.1. Central Retinal Vein Occlusion
  • 6.3.2. Branch Retinal Vein Occlusion
• 6.4. Market Attractiveness By Disease Type

7. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Treatment Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Treatment Type, 2020-2034
  • 7.3.1. Pharmacological Treatment
    • 7.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 7.3.1.2. Corticosteroid Drugs
  • 7.3.2. Laser Treatment
    • 7.3.2.1. Panretinal Photocoagulation
    • 7.3.2.2. Focal Laser
  • 7.3.3. Vitrectomy
• 7.4. Market Attractiveness By Treatment Type

8. Global Retinal Vein Occlusion Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020-2034
  • 8.3.1. Hospitals and Ambulatory Surgical Centers
  • 8.3.2. Ophthalmology Clinics
  • 8.3.3. Retail Pharmacies
  • 8.3.4. Others
• 8.4. Market Attractiveness By End-user

9. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Retinal Vein Occlusion Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Disease Type, 2020-2034
  • 10.2.1. Central Retinal Vein Occlusion
  • 10.2.2. Branch Retinal Vein Occlusion
• 10.3. Market Value Forecast By Treatment Type, 2020-2034
  • 10.3.1. Pharmacological Treatment
    • 10.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 10.3.1.2. Corticosteroid Drugs
  • 10.3.2. Laser Treatment
    • 10.3.2.1. Panretinal Photocoagulation
    • 10.3.2.2. Focal Laser
  • 10.3.3. Vitrectomy
• 10.4. Market Value Forecast By End-user, 2020-2034
  • 10.4.1. Hospitals and Ambulatory Surgical Centers
  • 10.4.2. Ophthalmology Clinics
  • 10.4.3. Retail Pharmacies
  • 10.4.4. Others
• 10.5. Market Value Forecast By Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Disease Type
  • 10.6.2. By Treatment Type
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Retinal Vein Occlusion Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Disease Type, 2020-2034
  • 11.2.1. Central Retinal Vein Occlusion
  • 11.2.2. Branch Retinal Vein Occlusion
• 11.3. Market Value Forecast By Treatment Type, 2020-2034
  • 11.3.1. Pharmacological Treatment
    • 11.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 11.3.1.2. Corticosteroid Drugs
  • 11.3.2. Laser Treatment
    • 11.3.2.1. Panretinal Photocoagulation
    • 11.3.2.2. Focal Laser
  • 11.3.3. Vitrectomy
• 11.4. Market Value Forecast By End-user, 2020-2034
  • 11.4.1. Hospitals and Ambulatory Surgical Centers
  • 11.4.2. Ophthalmology Clinics
  • 11.4.3. Retail Pharmacies
  • 11.4.4. Others
• 11.5. Market Value Forecast By Country / Sub-region, 2020-2034
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Disease Type
  • 11.6.2. By Treatment Type
  • 11.6.3. By End-user
  • 11.6.4. By Country / Sub-region

12. Asia Pacific Retinal Vein Occlusion Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Disease Type, 2020-2034
  • 12.2.1. Central Retinal Vein Occlusion
  • 12.2.2. Branch Retinal Vein Occlusion
• 12.3. Market Value Forecast By Treatment Type, 2020-2034
  • 12.3.1. Pharmacological Treatment
    • 12.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 12.3.1.2. Corticosteroid Drugs
  • 12.3.2. Laser Treatment
    • 12.3.2.1. Panretinal Photocoagulation
    • 12.3.2.2. Focal Laser
  • 12.3.3. Vitrectomy
• 12.4. Market Value Forecast By End-user, 2020-2034
  • 12.4.1. Hospitals and Ambulatory Surgical Centers
  • 12.4.2. Ophthalmology Clinics
  • 12.4.3. Retail Pharmacies
  • 12.4.4. Others
• 12.5. Market Value Forecast By Country / Sub-region, 2020-2034
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Disease Type
  • 12.6.2. By Treatment Type
  • 12.6.3. By End-user
  • 12.6.4. By Country / Sub-region

13. Latin America Retinal Vein Occlusion Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Disease Type, 2020-2034
  • 13.2.1. Central Retinal Vein Occlusion
  • 13.2.2. Branch Retinal Vein Occlusion
• 13.3. Market Value Forecast By Treatment Type, 2020-2034
  • 13.3.1. Pharmacological Treatment
    • 13.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 13.3.1.2. Corticosteroid Drugs
  • 13.3.2. Laser Treatment
    • 13.3.2.1. Panretinal Photocoagulation
    • 13.3.2.2. Focal Laser
  • 13.3.3. Vitrectomy
• 13.4. Market Value Forecast By End-user, 2020-2034
  • 13.4.1. Hospitals and Ambulatory Surgical Centers
  • 13.4.2. Ophthalmology Clinics
  • 13.4.3. Retail Pharmacies
  • 13.4.4. Others
• 13.5. Market Value Forecast By Country / Sub-region, 2020-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Disease Type
  • 13.6.2. By Treatment Type
  • 13.6.3. By End-user
  • 13.6.4. By Country / Sub-region

14. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Disease Type, 2020-2034
  • 14.2.1. Central Retinal Vein Occlusion
  • 14.2.2. Branch Retinal Vein Occlusion
• 14.3. Market Value Forecast By Treatment Type, 2020-2034
  • 14.3.1. Pharmacological Treatment
    • 14.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
    • 14.3.1.2. Corticosteroid Drugs
  • 14.3.2. Laser Treatment
    • 14.3.2.1. Panretinal Photocoagulation
    • 14.3.2.2. Focal Laser
  • 14.3.3. Vitrectomy
• 14.4. Market Value Forecast By End-user, 2020-2034
  • 14.4.1. Hospitals and Ambulatory Surgical Centers
  • 14.4.2. Ophthalmology Clinics
  • 14.4.3. Retail Pharmacies
  • 14.4.4. Others
• 14.5. Market Value Forecast By Country / Sub-region, 2020-2034
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Disease Type
  • 14.6.2. By Treatment Type
  • 14.6.3. By End-user
  • 14.6.4. By Country / Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Bayer AG
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Alimera Sciences
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Abbivie
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Annexin Pharmaceuticals AB
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. F. Hoffmann-La Roche AG
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Novartis AG
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. IRIDEX Corporation
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Lumenis
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Nidek Co., Ltd.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Regeneron Pharmaceuticals, Inc.
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments